54 related articles for article (PubMed ID: 32001948)
1. Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib.
Liu J; Lin S; Huynh A; Tan W
Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38258127
[TBL] [Abstract][Full Text] [Related]
2. Localization of Sites of Osimertinib Action in Rat Intestine, Skin, and Lung by Immunohistochemistry.
Yamamoto Y; Saita T; Kataoka H; Sogawa R; Kimura S; Kimura S; Shimanoe C; Shin M
Acta Histochem Cytochem; 2023 Dec; 56(6):145-151. PubMed ID: 38318107
[TBL] [Abstract][Full Text] [Related]
3. Intestinal Haemorrhage and Colitis Induced by Treatment With Osimertinib for Non-Small-Cell Lung Carcinoma: A Case Report.
Shujun W; Lili L; Lei Y; Feng W; Hefeng Z
Front Pharmacol; 2022; 13():854277. PubMed ID: 35479327
[No Abstract] [Full Text] [Related]
4. Localization and Accumulation Studies of Dacomitinib in Rat Intestines and Skin by Immunohistochemistry.
Yamamoto Y; Saita T; Oka A; Kataoka H; Shin M
Acta Histochem Cytochem; 2019 Dec; 52(6):101-106. PubMed ID: 32001948
[TBL] [Abstract][Full Text] [Related]
5. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
Nagano T; Tachihara M; Nishimura Y
Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
Lavacchi D; Mazzoni F; Giaccone G
Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
[TBL] [Abstract][Full Text] [Related]
7. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.
Lau SCM; Batra U; Mok TSK; Loong HH
Drugs; 2019 Jun; 79(8):823-831. PubMed ID: 31069718
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical localization of afatinib in male rat intestines and skin after its oral administration.
Yamamoto Y; Saita T; Yamamoto Y; Sogawa R; Kimura S; Narisawa Y; Kimura S; Shin M
Acta Histochem; 2019 Nov; 121(8):151439. PubMed ID: 31500866
[TBL] [Abstract][Full Text] [Related]
9. Development of a competitive enzyme-linked immunosorbent assay for therapeutic drug monitoring of afatinib.
Sogawa R; Saita T; Yamamoto Y; Kimura S; Narisawa Y; Kimura S; Shin M
J Pharm Anal; 2019 Feb; 9(1):49-54. PubMed ID: 30740257
[TBL] [Abstract][Full Text] [Related]
10. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS
Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502
[TBL] [Abstract][Full Text] [Related]
11. Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats.
Van Sebille YZA; Gibson RJ; Wardill HR; Secombe KR; Ball IA; Keefe DMK; Finnie JW; Bowen JM
Int J Cancer; 2017 Jun; 140(12):2820-2829. PubMed ID: 28316082
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
